Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations

PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease

Lale Kostakoglu, Morton Coleman, John P. Leonard, Ichiei Kuji, Holly Zoe and Stanley J. Goldsmith
Journal of Nuclear Medicine August 2002, 43 (8) 1018-1027;
Lale Kostakoglu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morton Coleman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John P. Leonard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ichiei Kuji
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Zoe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanley J. Goldsmith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    In entire group of patients who underwent 18F-FDG PET after first cycle of chemotherapy (30 patients), Kaplan-Meier estimate of PFS for 15 patients with positive 18F-FDG PET results is compared with that for 15 patients with negative 18F-FDG PET results after first cycle of chemotherapy. Statistically significant difference in PFS was found between positive and negative 18F-FDG PET results (P < 0.001).

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    In group of patients who underwent both early and late 18F-FDG PET (23 patients), Kaplan-Meier estimate of PFS for 6 patients with positive 18F-FDG PET results is compared with that for 17 patients with negative 18F-FDG PET results at completion of chemotherapy. Statistically significant difference in PFS was found between positive and negative 18F-FDG PET results (P = 0.001).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    A 35-y-old man with bulky HD underwent 18F-FDG PET before (A), after first cycle of (B), and at completion of (C) chemotherapy. Pretherapy 18F-FDG PET images reveal radiotracer uptake in anterior mediastinum involving both hilar regions and extending into left supraclavicular region. Patient underwent chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine. 18F-FDG PET after first cycle of chemotherapy reveals residual disease in right anterior mediastinum, whereas 18F-FDG PET at completion of chemotherapy shows no evidence of residual lymphoma in corresponding regions. Disease relapsed in mediastinum after PFS of 6 mo. Images obtained after first cycle show physiologic uptake in salivary glands, oral mucosa, right shoulder (trapezius muscle), and heart.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    A 45-y-old man with NHL underwent 18F-FDG PET before (A), after first cycle of (B), and at completion of (C) chemotherapy. Pretherapy 18F-FDG PET images reveal radiotracer uptake in nasopharynx and left cervical lymph nodes. Patient underwent chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone. Both after first cycle and at completion of chemotherapy, 18F-FDG PET reveals no evidence of residual disease. Disease was still in remission after PFS of 18 mo. All images show physiologic uptake in heart.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    In group of patients who underwent both early and late 18F-FDG PET (23 patients), Kaplan-Meier estimate of PFS for 10 patients with positive 18F-FDG PET results is compared with that for 13 patients with negative 18F-FDG PET results after first cycle of chemotherapy. Statistically significant difference in PFS was found between positive and negative 18F-FDG PET results (P < 0.001).

Tables

  • Figures
    • View popup
    TABLE 1

    Patient Characteristics

    CharacteristicAll patients (n = 30)Patients examined twice* (n = 23)
    Age (y)
     Mean ± SD52.3 ± 16.050.1 ± 14.0
     Range26–7726–77
    Sex
     Male1612
     Female1411
    Histologic diagnosis
     NHL (n = 17)
      Diffuse large B-cell lymphoma1310
      Follicular large cell lymphoma22
      Lymphoblastic lymphoma21
     HD (n = 13)1310
    No. of patients examined
     At initial staging1713
     At relapse1310
    • ↵* These patients had 18F-FDG PET studies both after first cycle and at completion of therapy.

    • View popup
    TABLE 2

    Characteristics of Patients with Relapse and with Poor Prognostic Features vs. Comparative 18F-FDG PET Results

    Patient no.Age (y)HistologyAnn Arbor stageTumor sizeAfter 1 cycleAfter completionOutcomePFS (mo)
    1>60DLCLIIIBBulky+− (FN)Relapse18
    2>60DLCLIIANonbulky+− (FN)Relapse10
    3<60DLCLIIBBulky+− (FN)Relapse6
    4>60FLCIIIABulky−−Remission24
    5<60HDIIBBulky+ (FP)+ (FP)Remission18
    6<60HDIIABulky−−Remission20
    7>60DLCLIIABulky−−Remission19
    8>60FLCIVNonbulky−−Remission20
    9DLCL+− (FN)Relapse7
    10DLCL++NFOD0
    11HD− (FN)+Relapse4
    12LL++NFOD0
    13HD+− (FN)Relapse5
    14DLCL++NFOD0
    15DLCL− (FN)− (FN)Relapse6
    16DLCL−−Remission18
    17HD++NFOD0
    18DLCL−−Remission18
    • After 1 cycle = 18F-FDG PET after first cycle of chemotherapy; After completion = 18F-FDG PET after completion of chemotherapy; DLCL = diffuse large cell lymphoma; FN = false-negative; FLC = follicular large cell lymphoma; FP = false-positive; NFOD = never free of disease; LL = lymphoblastic lymphoma.

      Patients 1–8 had poor prognostic features at initial staging; patients 9–18 were included in study at relapse.

    • View popup
    TABLE 3

    18F-FDG PET After 1 Cycle of Chemotherapy

    Category18F-FDG PET +18F-FDG PET −
    Relapse132
    Remission213
    Total1515
    Median PFS* (mo)0Not reached
    • ↵* Statistically significant difference between negative and positive 18F-FDG PET results (P < 0.0001).

    • Sensitivity = 87%; specificity = 87%; negative predictive value = 87%; positive predictive value = 87%; accuracy = 87%.

    • View popup
    TABLE 4

    18F-FDG PET After 1 Cycle vs. After Completion of Chemotherapy

    CategoryAfter 1 cycleAfter completion
    18F-FDG PET +18F-FDG PET −18F-FDG PET +18F-FDG PET −
    Relapse9256
    Remission111111
    Total1013617
    Median PFS (mo)5Not reached0Not reached
    • View popup
    TABLE 5

    Overall Comparative Analysis

    IndexAll patients* (n = 23)Patients with poor prognosis† (n = 18)
    After 1 cycle (%)After completion (%)After 1 cycle (%)After completion (%)
    Sensitivity8245.58245.5
    Specificity92928686
    Negative predictive value85657550
    Positive predictive value90839083
    Accuracy87708361
    • ↵* These patients had data available for 18F-FDG PET performed after first and last cycles.

    • ↵† These patients were entered in study at relapse before salvage therapy or had poor prognostic features at initial staging.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 43 (8)
Journal of Nuclear Medicine
Vol. 43, Issue 8
August 1, 2002
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease
Lale Kostakoglu, Morton Coleman, John P. Leonard, Ichiei Kuji, Holly Zoe, Stanley J. Goldsmith
Journal of Nuclear Medicine Aug 2002, 43 (8) 1018-1027;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease
Lale Kostakoglu, Morton Coleman, John P. Leonard, Ichiei Kuji, Holly Zoe, Stanley J. Goldsmith
Journal of Nuclear Medicine Aug 2002, 43 (8) 1018-1027;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma
  • Validation of Several SUV-Based Parameters Derived from 18F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer
  • Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
  • 18F-FDG PET/CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast Cancer
  • Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab
  • Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications
  • PET/CT with 18F-FLT: Does It Improve the Therapeutic Management of Metastatic Germ Cell Tumors?
  • Mixed Response in Interim Positron Emission Tomography/Computed Tomography Leads to Detection of a Gastrointestinal Stromal Tumor in a Patient With Mediastinal Diffuse Large B-Cell Lymphoma
  • Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial
  • Tumor Metabolic Phenotypes on 18F FDG PET
  • PET/CT for Therapy Response Assessment in Lymphoma
  • Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
  • Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
  • Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy
  • Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors
  • Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
  • Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
  • Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
  • A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer
  • Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
  • Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma
  • Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT
  • Effect of Corticosteroids on 18F-FDG Uptake in Tumor Lesions After Chemotherapy
  • Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
  • Revised Response Criteria for Malignant Lymphoma
  • Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
  • Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
  • Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin's Disease
  • The Role of PET in Lymphoma
  • Positron Emission Tomography As an Imaging Biomarker
  • Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma
  • FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
  • Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma
  • PET for response assessment in oncology: radiotherapy and chemotherapy
  • [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
  • Role of Positron Emission Tomography in Lymphoma
  • Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
  • Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
  • Imaging DNA Synthesis In Vivo with 18F-FMAU and PET
  • Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease
  • Decreased 18F-FDG Uptake 1 Day After Initiation of Chemotherapy for Malignant Lymphomas
  • Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use
  • Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484
  • PET/CT in Oncology: Integration into Clinical Management of Lymphoma, Melanoma, and Gastrointestinal Malignancies
  • Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice
  • PET Scans in the Staging of Lymphoma: Current Status
  • Prognostic Value of PET Using 18F-FDG in Hodgkin's Disease for Posttreatment Evaluation
  • Early Response to Chemotherapy in Hypopharyngeal Cancer: Assessment with 11C-Methionine PET, Correlation with Morphologic Response, and Clinical Outcome
  • 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
  • Assessment of Lymphoma Therapy Using 18F-FDG PET
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire